Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com’s coverage highlights our three biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
3. 3M loses British BacLite case, claims victory anyway
3M Co. (NYSE:MMM) may have lost $1.3 million in a long-running lawsuit over its BacLite diagnostic test, but the conglomerate is declaring victory anyway after dodging a potential $40 million in damages and pressing ahead in a lawsuit against a prominent Washington lobbyist and the head of the investment firm that backed BacLite.
Sign up to get our free newsletters delivered straight to your inbox
2. Is Becton Dickinson ripe for a buyout?
Becton Dickinson & Co. (NYSE:BDX) is at its lowest valuation since 1993, making it ripe for a buyout, after reporting dismal third-quarter results last week. The company posted a 24 percent profit slide for the quarter Nov. 2, sending shares down 4.6 percent to a close of $72.60 that day.
1. Edwards and Medtronic tout regulatory wins for valve treatments
Medtronic Inc. (NYSE:MDT) and Edwards Lifesciences (NYSE:EW) both got the thumbs up for their heart valves from regulatory bodies, but Edwards is ahead of Medtronic in bringing a device to the U.S. market with FDA approval to expand clinical trials of its Sapien system.
